Article · 29 Dec 2025
Conference abstractPublished 19 Oct 2016
Using IPRs in the biosimilars context
Sheppard, Mullin, Richter & Hampton LLP, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In Amgen v. Sandoz, the Federal Circuit held that biosimilar applicants are not required to provide their Biologics License Application (BLA) or engage in the patent dance âÂ?Â? the process under the BPCIA in which the parties identify which patents the parties believe should be litigated. However, the court held that an applicant who fails to provide its BLA must provide the brand with 180-daysâÂ?Â? notice of launch. In Amgen v. Apotex, the Federal Circuit held that a biosimilar applicant must always provide the brand with 180-daysâÂ?Â? notice before launch, regardless of whether the applicant provided its BLA or engaged in the patent dance. The result of these decisions may be that few biosimilars applicants engage in the patent dance. Rather than litigating biologics patents under the BPCIA, biosimilars applicants may challenge biologics patents by filing IPRs. We will review IPRs that have been filed in the biologics area, analyze key institution decisions, and provide takeaways from the institution decisions and our views on lessons that should be learned from these decisions.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Laura Burson”

